

Apollo Medical Holdings, Inc.  
Form NT 10-Q  
August 17, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 12b-25**

---

**NOTIFICATION OF LATE FILING**

*(Check One)*:  Form 10-K    Form 20-F    Form 11-K    Form 10-Q    Form 10-D  
 Form N-SAR

For Period Ended: 6-30-2015

- Transition Report on Form 10-K
- Transition Report on Form 20-F
- Transition Report on Form 11-K
- Transition Report on Form 10-Q
- Transition Report on Form N-SAR

For the Transition Period Ended: N/A

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:  
N/A

**PART I— REGISTRANT INFORMATION**

**Apollo Medical Holdings, Inc.**

---

Full Name of Registrant

700 North Brand Blvd, Suite 220

---

Address of Principal Executive Office (Street and Number)

Glendale, California 91203

---

City, State and Zip Code

**PART II — RULES 12b-25(b) AND (c)**

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

(a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;

(b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K or Form N-SAR, Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and

(c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

**PART III — NARRATIVE**

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The compilation, dissemination and review of the information required to be presented in the Form 10-Q for the relevant period has imposed time constraints that have rendered timely filing of the Form 10-Q impracticable without undue hardship and expense to the registrant. The registrant expects to file such report no later than five days after its original prescribed due date.

**PART IV—OTHER INFORMATION**

(1) Name and telephone number of person to contact in regard to this notification

Warren Hosseinion M.D. (818) 839-5200  
(Name) (Area Code) (Telephone Number)

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).  Yes  No

(3) Is it anticipated that any significant change in results of operation for the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof?

Yes  No

The Company has experienced organic growth, made various acquisitions and entered into various strategic transactions during the periods since the quarter ended June 30, 2014 that have had a significant effect on the Company's results of operations. As a result, for the three months ended June 30, 2015, compared to the three months ended June 30, 2014, the Company currently expects net revenues will have increased to approximately \$10.2 million from approximately \$4.1 million and net loss will have increased to approximately \$2.3 from approximately \$1.5

million.

**Apollo Medical Holdings, Inc.**

---

(Name of Registrant as Specified in Charter)

Has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 14, 2015 By: /s/ Warren Hosseinion M.D.

Warren Hosseinion M.D.

Chief Executive Officer